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Objective. Assess risk of cardiac events and mortality among users of olanzapine and other antipsychotics relative to nonusers.
Methods.TheGeneral Practice Research Database was used to identify cohorts of antipsychotic users and nonusers with psychiatric
illness. Outcomes included cardiac mortality, sudden cardiac death (SCD), all-cause mortality (excluding suicide), coronary heart
disease (CHD), and ventricular arrhythmias (VA). Results. 183,392 antipsychotic users (including 20,954 olanzapine users) and
193,920 psychiatric nonusers were identified.There was a significantly higher rate of cardiac mortality (adjusted RR [aRR]: 1.53, CI,
1.12–2.09) in olanzapine users relative to psychiatric nonusers, consistent with findings for both atypical and typical antipsychotics.
Relative to psychiatric nonusers, no increased risk of all-causemortality was observed among olanzapine users (aRR: 1.04, CI, 0.93–
1.17), but elevated all-cause mortality risk was observed when compared to all antipsychotic users (aRR: 1.75, CI, 1.64–1.87). There
was no increased risk of CHD or VA among olanzapine users relative to psychiatric nonusers, consistent with findings for atypical
but not typical antipsychotics. SCD cases were uncommon. Conclusions. Use of antipsychotic agents was associated with increased
risk of all-cause and cardiacmortality. Patients treated with olanzapine were found to be at increased risk of cardiacmortality versus
psychiatric nonusers.
1. Introduction
It is generally accepted that that there is an increased risk of
mortality (including sudden cardiac death (SCD)) and major
cardiac events during treatment with some antipsychotics in
patients with schizophrenia and other mental illnesses [1–
5]. Several large observational studies have been conducted
in recent years to assess the extent of increased risk with
these outcomes in antipsychotic users and to differentiate risk
with typical and atypical antipsychotics. In a retrospective
cohort study of Medicaid enrollees in Tennessee, Ray et
al. [2] found that current users of typical and atypical
antipsychotics had a similar, dose-related increased risk of
sudden cardiac death. The primary objective of the present
retrospective observational study was to assess the risks of
sudden cardiac death and cardiac mortality among users
of the antipsychotic product olanzapine. The risk associated
with olanzapine prescribing was assessed relative to psychi-
atric patients who did not use antipsychotic medications
(nonusers) and among groups of antipsychotic medication
2 Cardiovascular Psychiatry and Neurology
users (atypical, typical, and any), as well as the risks among
users of individual antipsychotic agents. Secondary outcomes
included all-cause mortality (excluding suicide) and several
nonfatal cardiovascular outcomes. Results evaluating risks
for antipsychotic users in general, relative to nonusers with
psychiatric illness and to the general population, are being
published elsewhere.This paper focuses on the risk associated
with olanzapine treatment relative to a nonuser psychiatric
population, presented in the context of risks associated with
other types of antipsychotics and individual antipsychotic
agents.
2. Methods
2.1. Study Population. The General Practice Research
Database (GPRD), now administered by the Clinical Practice
Research Datalink, was used to identify populations for
the study. GPRD comprises anonymised computerised
medical records from primary care for about 8% of the UK
population. At the time of the study, about 40% of GPRD
practices also participated in anonymous and patient-level
linkages to the national registry of hospital admission
(Hospital Episode Statistics (HES)) and death certificates
(as collected by the Office of National Statistics (ONS)). The
base population was comprised of all acceptable patients
registered in GPRD from January 1995 to January 2011. The
study populations were limited to acceptable patients from
up-to-standard practices to ensure the quality of the data.
Patient acceptability is based on eleven assessment criteria
defined by the GPRD to ensure that registered patients meet
basic research quality standards. Up-to-standard practices
are general surgery practices that meet a practice-based
quality marker indicating when a practice has reached an
acceptable level of data entry quality and thus are considered
to have continuous high quality data.
Patients were also required to be registered in GPRD for
at least one year prior to the index date (cohort entry date) to
ensure adequate assessment ofmedical history and prior drug
usage. Patients with a history of life-threatening ventricular
tachyarrhythmia, cardioversion, aborted cardiac arrest, or
implantation of a cardiac defibrillator in the baseline period
were excluded. Patients with a congenital conduction disor-
der or advanced cardiomyopathy (hypertrophic or dilated)
prior to the index date or at any time during follow-up were
also excluded. HES data were available from April 1997 and
death certificates from January 2001. The data from HES,
death certificates, and GPRD were recorded and collected
independently from each other.
One cohort of current antipsychotic users was classified
at the index date (first date of antipsychotic prescribing in
the study period) into prevalent and incident antipsychotic
users: incident users were those with a first-ever prescription;
prevalent users were those who received an antipsychotic
prescription before index. For some analyses, this cohort was
further subdivided by type of antipsychotic (typical versus
atypical, or by specific antipsychotic).
A cohort of patients with a diagnosis of schizophrenia,
bipolar disorder/other mood disorders, major depression,
or dementia but without a history of use of antipsychotics,
referred to as psychiatric nonusers, was also identified. For
this cohort, the index date was defined as the date of the
first record of the psychiatric disorder (i.e., both incident and
prevalent cases were included). Patients were censored at the
earliest of their deregistration date at the practice, the date
of their first antipsychotic prescription after their diagnosis
date (if they remained registered at the practice), the last
collection date of the practice, or the end of the study period.
This cohort was not matched to the cohort of antipsychotic
users; rather, baseline differences were adjusted for using
multivariate analysis.
For both cohorts, patients were followed from the index
date up to the occurrence of the outcome of interest or the
end of data collection (i.e., last GPRDdata collection, transfer
out of the practice, or date of death, whichever date came
first). For antipsychotic users, the follow-up was restricted
to “current exposure,” defined as the period from the initial
antipsychotic prescription up to onemonth after the expected
end of treatment.The defined daily dose (DDD) for prescrip-
tions was calculated based on the prescribed daily dose and
strength per tablet. These DDDs were then classified as low,
medium, or high dose using the dose thresholds for antipsy-
chotics defined in terms of chlorpromazine equivalents [6].
Low daily dose was defined as <200mg, medium as 200–
399mg, and high as≥400mg chlorpromazine equivalents per
day.
Duration of use was calculated from cohort entry date
to the expected end of the last prescription occurring prior
to their censor date. Duration of use was defined as the
prescription quantity divided by daily dose. Where the
estimated duration was missing or corresponded to approxi-
mately the 1st and 99th percentiles of the distribution of all
estimated prescription durations, estimated durations were
imputed using the median for that prescription. Patients
whose duration of use could not be estimated in this waywere
assigned the median pertaining to the subtype of the antipsy-
chotic substance instead. About 13% of all prescriptions were
imputed. The cumulative treatment duration at the end of
follow-up for all exposed patients was calculated as tertiles
which corresponded broadly to <1 year, 1–3 years, or >3 years
of use.
2.2. Ascertainment of Outcomes of Interest. The outcomes
of interest included cardiac mortality, three definitions for
sudden cardiac death (SCD), all-cause mortality excluding
suicide (referred to as all-cause mortality from here on out),
coronary heart disease (CHD), and life-threatening ventricu-
lar arrhythmias (VA). Outcomes were identified using GPRD
Read codes, ICD10 codes fromONSdeath certificate data and
records from HES (Table 1).
When querying multiple sources for the occurrence of
an outcome, the following hierarchy was used, with earlier-
named sources taking precedence over the later-named
sources when more than one was available for any given
patient: death certificate (both the recorded date and cause
of death), followed by GPRD free text (date of death taken to
be the earlier of the recorded GPRD date of death or free text
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Table 1: Definitions for Outcomes of Interest.
All-cause
mortality Deaths due to any cause except suicide.
Cardiac
Mortality
Based on death certificates with ICD 10 codes
I10, I11.9, I20, I21, I22, I23, I24, I25, I42.8, I42.9,
I46, I47, I49.0, I49.8, I49.9, I51.6, I51.9, I70.9,
R09.2, R96, R98.
SCD primary
definition
This was a narrow definition of SCD and the
most restrictive. The SCD diagnosis was
derived from the following ICD10 codes
recorded on death certificates (available from
January 1998 to November 2010): I46, I47.2,
I49.0, R09.2, R96 [10], from Read codes in
GPRD that correspond to these ICD10 codes,
or from free text in the ± 3 weeks before or
after the death recording. Data from a national
registry of hospital admission (Hospital
Episode Statistics (HES), available from April
1997 to October 2010) were used to ensure that
the event took place outside the hospital. A
mortality event that occurred within 30 days
after the hospital discharge date was not
included in the SCD definition.
SCD secondary
definition
This definition is broader than the primary
definition and is similar to the definition used
by Ray et al. (2009) [2]. The SCD diagnosis was
derived from death certificates with ICD 10
codes I10, I11.9, I20, I21, I22, I23, I24, I25, I42.8,
I42.9, I46, I47, I49.0, I49.8, I49.9, I51.6, I51.9,
I70.9, R09.2, R96.1, R98, from Read codes in
GPRD that correspond to these ICD10 codes,
or from free text in the ± 3 weeks before or
after the death recording. Cases with a HES
record of hospitalisation were excluded.
SCD tertiary
definition
This definition was the same as the secondary
definition with the exception that only data
from GPRD, and not from death certificates or
HES, were used.
SCD (based on
free text)
The following text strings were used to identify
sudden cardiac death from GPRD free text:
“dropped dead”, “died unexpectedly”, “sudden
cardiac death”, “death” and “cause unk”, “acute
cardiac death”, “unexpected” and “death”, “mors
subita”, “death instanta”, “died instanta”, “sudden
death”, “dropped death”, and “died suddenly”.
CHD
Based on GPRD Read codes; data from a
national registry of hospital admission
(Hospital Episode Statistics (HES)) ICD10
codes I21 or I22; or cardiac procedures)
Life-threatening
ventricular
arrhythmias
Based on GPRD Read codes or HES ICD10
I49.0.
date), followed byGPRDRead code (date of death taken to be
the earlier of the recorded GPRD date of death or the date of
Read code).Where both aRead code and a free text termwere
recorded, the earlier of the two events was considered as the
date of the event. For example, if under the sudden cardiac
death primary definition a patient would be considered
a case based on the GPRD Read codes but not on their
cause of death, then the patient was not recorded as a case.
However, if the definition was based on GPRD Read codes
the patient would be considered a case supporting evidence
from free text was not also needed. A conservative approach
in identifying the SCD cases was used, counting them as SCD
cases unless the free text clearly specified another cause of
death. In addition, GPRD free text information was used to
improve the odds of accurately identifying SCD cases. For
relevant cases from practices shown to use an above-median
amount of free text, 2 independent experts reviewed free
text surrounding search string terms suggestive of sudden
cardiac death (Table 1) and identified events appropriate for
inclusion.
2.3. Statistical Analyses. Poisson regression analysis was used
to examine the rates of each outcome and produce corre-
sponding age- and sex-adjusted (RRs) and fully adjusted
relative ratios (aRRs) and 95% confidence intervals (CI)
for each comparison. Adjusted models were fitted using
automated backward eliminationwith stepwise regression. To
ensure that the resultingmodels were not overparameterised,
the number of variables to be included in the model was
selected using the rule of thumb of five outcome events per
parameter [7, 8]. Goodness-of-fit was assessed by examining
the associated 𝑃 values of the covariates such that a covariate
was included in the model only if the associated 𝑃 value was
<0.05, while any covariates in the model with 𝑃 values ≥
0.10 were excluded.The following patient characteristics were
considered as potential confounders in regression models:
age, sex, socioeconomic status (Index ofMultipleDeprivation
calculated at the postcode of the patient’s residence), smoking
history, alcohol use, and body mass index (BMI). Age, sex,
and treatment were included in the model a priori. BMI
was calculated using the most recent BMI measurement
available before the index date. Nonsmokers were classified
as patients with a history of nonsmoking only, documented
in their record. Current smoking was based on the most
recent smoking record of the patient documented before the
index date. Regression models included indicator variables
for missing values for BMI and smoking. Other confounding
factors included time since start of GPRD data collection (in
tertiles); duration of psychiatric disease; history of cardiovas-
cular disease; alcohol or drug abuse; diabetesmellitus; history
of suicide attempt; prior hospital admission for psychiatric
disease; and prescribing in the previous 3 months of statins
or fibrates, antihypertensive drugs, warfarin, antiplatelets,
nitrates, lithium, antiepileptics, antidepressants, and anxi-
olytics. To examine changes in risk over time, patient follow-
up (from start of medication until end of data collection) was
subdivided into 100 periods of equal length and incidence
rates (hazard rates) were estimated for each period. These
rateswere smoothed using themethods proposed byRamlau-
Hansen [9]. Analyses were conducted using STATA 11.
3. Results
The study identified 183,392 antipsychotic users (typical or
atypical), including 20,954 olanzapine users (11.4%), and
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Table 2: Baseline characteristics of the patients exposed to antipsychotics and unexposed diseased patients.
Characteristic
Exposed to
antipsychotics
(N = 183,392)
Typical
antipsychotics
(N = 115,491)
Atypical
antipsychotics
(N= 67,901)
Olanzapine
(N = 20,954)
Psychiatric
nonuser
(N = 193,920)
Prevalent users 67,396 (36.7%) 40,258 (34.9%) 27,138 (40.0%) 9016 (43.0%) 0 (0.0%)
Female 107,226 (58.5%) 69,426 (60.1%) 37,800 (55.7%) 10,296 (49.1%) 132,458 (68.3%)
Male 76,166 (41.5%) 46,065 (39.9%) 30,101 (44.3%) 10,658 (50.9%) 61,462 (31.7%)
Age: mean (sd) 60 (22) 61 (21) 58 (23) 49 (20) 52 (22)
Age: median (IQR) 62 (41–80) 64 (44–80) 58 (38–81) 45 (33–64) 48 (33–75)
Age 18–29 18,474 (10.1%) 9,180 (7.9%) 9,294 (13.7%) 3759 (17.9%) 34,559 (17.8%)
Age 30–39 23,484 (12.8%) 13,747 (11.9%) 9,737 (14.3%) 4237 (20.2%) 38,574 (19.9%)
Age 40–49 23,793 (13.0%) 14,554 (12.6%) 9,239 (13.6%) 3953 (18.9%) 28,555 (14.7%)
Age 50–59 21,244 (11.6%) 14,627 (12.7%) 6,617 (9.7%) 2806 (13.4%) 21,302 (11.0%)
Age 60–69 19,923 (10.9%) 14,461 (12.5%) 5,462 (8.0%) 1,992 (9.5%) 13,831 (7.1%)
Age 70–79 28,088 (15.3%) 18,881 (16.3%) 9,207 (13.6%) 1,948 (9.3%) 21,194 (10.9%)
Age 80+ 48,386 (26.4%) 30,041 (26.0%) 18,345 (27.0%) 2,259 (10.8%) 35,905 (18.5%)
BMI: mean (sd) 26 (6) 26 (5) 26 (6) 26 (5) 26 (6)
Nonsmoker 69,482 (37.9%) 44,035 (38.1%) 25,447 (37.5%) 6,771 (32.3%) 80,061 (41.3%)
Exsmoker 29,719 (16.2%) 17,638 (15.3%) 12,081 (17.8%) 2,877 (13.7%) 39,550 (20.4%)
Smoker 51,938 (28.3%) 31,361 (27.2%) 20,577 (30.3%) 8,350 (39.8%) 57,004 (29.4%)
Unknown status 32,253 (17.6%) 22,457 (19.4%) 9,796 (14.4%) 2,956 (14.1%) 17,305 (8.9%)
Hx alcoholism or drug abuse 19,933 (10.9%) 11,429 (9.9%) 8,504 (12.5%) 3,544 (16.9%) 12,572 (6.5%)
Hx suicide attempts 10,777 (5.9%) 5,762 (5.0%) 5,015 (7.4%) 2,015 (9.6%) 8,841 (4.6%)
Schizophrenia 15,475 (8.4%) 6,746 (5.8%) 8,729 (12.9%) 3,750 (17.9%) 7,779 (4.0%)
Bipolar/other mood disorders 7,368 (4.0%) 3,170 (2.7%) 4,198 (6.2%) 2,008 (9.6%) 4,700 (2.4%)
Major depression 19,981 (10.9%) 11,680 (10.1%) 8,301 (12.2%) 3,343 (16.0%) 134,105 (69.2%)
Dementia 25,174 (13.7%) 12,669 (11.0%) 12,505 (18.4%) 1,291 (6.2%) 47,336 (24.4%)
No recorded psychiatric disorders 115,394 (62.9%) 81,226 (70.3%) 34,168 (50.3%) 10,562 (50.4%) 0 (0.0%)
Diabetes 15,276 (8.3%) 9,480 (8.2%) 5,796 (8.5%) 1,047 (5.0%) 13,639 (7.0%)
Acute MI 6,530 (3.6%) 4,224 (3.7%) 2,306 (3.4%) 380 (1.8%) 5,466 (2.8%)
Statins/fibrates in previous 3mo. 16,203 (8.8%) 8,406 (7.3%) 7,797 (11.5%) 1,464 (7.0%) 18,124 (9.3%)
Antiplatelets 32,260 (17.6%) 18,900 (16.4%) 13,360 (19.7%) 2,096 (10.0%) 25,397 (13.1%)
Antidepressants 83,595 (45.6%) 49,545 (42.9%) 34,050 (50.1%) 11,487 (54.8%) 126,688 (65.3%)
Anxiolytics 27,389 (14.9%) 15,637 (13.5%) 11,752 (17.3%) 3,898 (18.6%) 12,907 (6.7%)
SSRIs 44,428 (24.2%) 24,330 (21.1%) 20,098 (29.6%) 6,757 (32.2%) 98,373 (50.7%)
Lithium 5,122 (2.8%) 2,851 (2.5%) 2,271 (3.3%) 1,053 (5.0%) 1,743 (0.9%)
Antiepileptics 10,090 (5.5%) 5,853 (5.1%) 4,237 (6.2%) 1,287 (6.1%) 3,817 (2.0%)
193,920 patients with psychiatric illness whowere not users of
typical or atypical antipsychotic drugs (psychiatric nonusers)
(Table 2). The average duration of follow-up time was 4.0
years (SD 4.0) for antipsychotic users, 3.6 years (SD 2.86) for
olanzapine users, and 4.1 years (SD 3.5) for patients with psy-
chiatric illness. The olanzapine and psychiatric nonuser pop-
ulations, which were notmatched tominimize heterogeneity,
differed in some respects. Whether these differences are
statistically or clinically significant is unknown.
This study assessed all-cause and cardiac mortality,
SCD, CHD and ventricular arrhythmias among patients
currently taking antipsychotic agents relative to nonusers of
antipsychotic drugs.
3.1. All-Cause and Cardiac Mortality. Significantly higher
risk for cardiac mortality was observed in patients currently
treated with olanzapine relative to nonusers with psychiatric
illness (aRR: 1.53, 95% CI, 1.12–2.09) (Table 3). This result is
consistent with cardiac mortality risk findings for antipsy-
chotic users in general (aRR: 1.72, 95%CI, 1.42–2.07). An
assessment of all-cause mortality found no increased risk for
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Table 3: Relative risks of all-cause mortality (excluding suicide) and cardiovascular outcomes for current users of various types of
antipsychotics versus nonuser psychiatric controls.
Outcome Exposure type Number ofevents PY
Incidence rate per
1000 PY
(95% CI)
Age-and
sex-adjusted
relative risk (RR)
(95% CI)
Fully adjusted RR
(aRR)
(95% CI)
All-cause
mortality
Nonuser psychiatric 7765 307,276 25.3 (24.7–25.8) Reference Reference
Atypical or typical 23,841 276,892 86.1 (85.0–87.2) 2.15 (2.10–2.21)‡ 1.75 (1.64–1.87)‡
Atypical 7356 94,112 78.2 (76.4–80.0) 1.76 (1.71–1.82)‡ 1.52 (1.40–1.64)‡
Typical 15473 167,005 92.7 (91.2–94.1) 2.34 (2.28–2.41)‡ 1.82 (1.69–1.98)‡
Olanzapine 1305 34,985 37.3 (35.3–39.4) 1.40 (1.32–1.48)‡ 1.04 (0.93–1.17)
Cardiac mortality
Nonuser psychiatric 1289 200,988 6.4 (6.1–6.8) Reference Reference
Atypical or typical 2478 145,643 17.0 (16.4–17.7) 1.62 (1.52–1.74)‡ 1.72 (1.42–2.07)‡
Atypical 1200 73,284 16.4 (15.5–17.3) 1.47 (1.36–1.59)‡ 1.74 (1.40–2.14)‡
Typical 1180 64,913 18.2 (17.2–19.3) 1.78 (1.64–1.92)‡ 1.88 (1.49–2.39)‡
Olanzapine 206 26,765 7.7 (6.7–8.8) 1.25 (1.07–1.44)‡ 1.53 (1.12–2.09)‡
SCD—primary
definition
Nonuser psychiatric 10 23,872 0.4 (0.2–0.8) Reference Reference
Atypical or typical 44 16,144 2.7 (2.0–3.7) 5.76 (2.90–11.45)‡ 5.76 (2.90–11.45)‡
Atypical 21 10,201 2.1 (1.3–3.2) 0 (NC) 0 (NC)
Typical 21 5415 3.9 (2.4–5.9) 0 (NC) 0 (NC)
Olanzapine 6 3454 1.7 (0.6–3.8) 0 (NC) 0 (NC)
SCD—secondary
definition
Nonuser psychiatric 98 23,873 4.1 (3.3–5.0) Reference Reference
Atypical or typical 178 16,144 11.0 (9.5–12.8) 2.36 (1.84–3.02)‡ 2.15 (1.64–2.81)‡
Atypical 90 10,201 8.8 (7.1–10.8) 1.93 (1.45–2.57)‡ 1.79 (1.33–2.42)‡
Typical 78 5415 14.4 (11.4–18.0) 2.82 (2.09–3.80)‡ 3.99 (1.29–12.40)†
Olanzapine 10 3454 2.9 (1.4–5.3) 1.33 (0.69– 2.57) 0 (NC)
SCD—tertiary
definition
Nonuser psychiatric 119 64,880 1.8 (1.5–2.2) Reference Reference
Atypical or typical 198 43,550 4.6 (3.9–5.2) 1.92 (1.53–2.42)‡ 1.79 (1.42–2.27)‡
Atypical 97 26,345 3.7 (3.0–4.5) 1.60 (1.22–2.09)‡ 1.51 (1.14–1.99)‡
Typical 96 15,621 6.2 (5.0–7.5) 2.39 (1.82–3.13)‡ 2.27 (1.71–3.01)‡
Olanzapine 15 8425 1.8 (1.0–2.9) 1.61 (0.93–2.77)∗ 0 (NC)
CHD
Nonuser psychiatric 982 278,330 3.5 (3.3–3.8) Reference Reference
Atypical or typical 1355 236,229 5.7 (5.4–6.1) 1.08 (1.00–1.18)∗ 1.16 (0.94–1.44)
Atypical 444 86,115 5.2 (4.7–5.7) 0.94 (0.84–1.05) 0.98 (0.76–1.26)
Typical 873 136,777 6.4 (6.0–6.8) 1.19 (1.09–1.31)‡ 1.39 (1.09–1.76)‡
Olanzapine 132 31,806 4.2 (3.5–4.9) 1.01 (0.84–1.21) 1.07 (0.76–1.49)
Ventricular
arrhythmias
Nonuser psychiatric 500 279,243 1.8 (1.6–2.0) Reference Reference
Atypical or typical 646 237,647 2.7 (2.5–2.9) 1.14 (1.01–1.28)† 1.16 (1.02–1.31)†
Atypical 230 86,319 2.7 (2.3–3.0) 1.05 (0.89–1.23) 1.06 (0.90–1.26)
Typical 382 137,982 2.8 (2.5–3.1) 1.16 (1.01–1.32)† 1.37 (1.00–1.87)∗
Olanzapine 55 31,921 1.7 (1.3–2.2) 0.90 (0.68–1.18) 0.86 (0.65–1.14)
∗
𝑃 < 0.10, †𝑃 < 0.05, ‡𝑃 < 0.01.
Abbreviations: aRR: adjusted relative risk; CHD: coronary heart disease; CI: confidence interval; NC: not calculated; PY: person-years; SCD: sudden cardiac
death.
patients treatedwith olanzapine relative to nonuserswith psy-
chiatric illness. In contrast, there was a significantly elevated
risk for all-cause mortality for antipsychotic users as a group
and other specific agents assessed (except perphenazine)
relative to nonusers with psychiatric illness (Table 4).
3.2. Sudden Cardiac Death. Due to small event counts, it
was not possible to do a comparative assessment of SCD
risk for patients treated with olanzapine (using any of the
3 definitions). Increased risks of SCD (secondary definition
(aRR: 2.15, 95% CI, 1.64–2.81) and tertiary definitions (aRR:
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Figure 1: Relative risks of all-cause mortality (excluding suicide) and cardiac mortality for current users of various types of antipsychotics
versus nonuser psychiatric controls stratified by age.
1.79, 95% CI, 1.42–2.27)) were observed for patients cur-
rently treated with antipsychotics relative to nonusers with
psychiatric illness (Table 3). As with the olanzapine cohort,
there were insufficient event counts to assess the primary
definition for typical and atypical users individually. Using
the secondary and tertiary definitions, current users of typical
antipsychotics had a highermagnitude of SCD risk than users
of atypical antipsychotics.
3.3. Coronary Heart Disease and Ventricular Arrhythmias.
There were no increased risks of CHD and ventricular
arrhythmias for patients currently treated with olanzapine
relative to nonusers with psychiatric illness (Table 3). For
both outcomes, this is consistent with findings for users
of other atypical antipsychotics. In the case of CHD, there
was a statistically significant increased risk among typical
antipsychotic users relative to nonusers.
3.4. Outcomes Stratified by Age. Olanzapine patients aged 30
to 64 had statistically significant increased risk of all-cause
mortality compared to nonusers with psychiatric illness from
the same age group (aRR: 1.51, 95% CI, 1.15–1.98) (Figure 1).
Olanzapine patients aged 65 to 79 had a small but significantly
increased all-cause mortality risk relative to nonusers with
psychiatric illness in this age group (aRR: 1.16, 95% CI,
1.03–1.31). Olanzapine patients 80 and above had statistically
significant lower all-cause mortality risk relative to nonusers
aged 80 and above (aRR: 0.84, 95% CI, 0.72–0.99). There
were not enoughmortality events among olanzapine patients
under the age of 30 to enable comparisons. This pattern of
findings, with higher relative risks from 30 to 64 year old
compared to the older age strata, was similar for the cardiac
mortality and CHD outcomes for olanzapine (data for CHD
not shown) and was also observed for all-cause and cardiac
mortality risk, for users of atypical agents, typical agents,
and antipsychotics in general. For both SCD and ventricular
arrhythmias, there were insufficient event counts to calculate
aRR by olanzapine age strata (data not shown).
3.5. Outcomes Stratified by Dose. Olanzapine users taking
medium and high doses had a significantly increased risk of
cardiac mortality relative to a nonuser psychiatric population
(Table 5). Significantly increased risk of cardiacmortality was
also observed at all dose levels for patients taking any atypical
or any typical antipsychotic agent.
Due to low counts of SCD among users of olanzapine,
risk for SCD could not be calculated by dose. Significantly
increased risks of SCD with increased dose were observed
for users of typical antipsychotics or for any antipsychotic;
however, there was no apparent pattern for users of atypical
antipsychotics, for whom the highest increased risk for SCD
was seen with low doses, followed by high and then medium
doses. It should be noted, however, that even in the larger
overall antipsychotic user groups, there were small event
counts (<15) in the medium- and high-dose strata, limiting
the interpretation of the results.
For all-cause mortality, there was no evidence of increas-
ing risk with increasing dose for patients treated with olan-
zapine or for patients treated with atypical antipsychotics in
general, relative to nonuser psychiatric patients. However,
patients treated with typical antipsychotics had increasing
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risk with increasing the dose from low (aRR of 1.76) to
medium (aRR of 3.74).
For CHD, there was no evidence of increasing risk
with increasing dose for patients treated with olanzapine,
atypical antipsychotics, or typical antipsychotics. The only
significant result was risk for patients receiving low-dose
typical antipsychotics.
For ventricular arrhythmia, there was no evidence of
increasing risk with increasing dose for patients treated
with olanzapine or for patients treated with atypical antipsy-
chotics in general, relative to nonuser psychiatric patients.
This is in contrast to patients using typical antipsychotics,
with markedly higher risk ratios for ventricular arrhythmias
among patients taking medium (aRR of 2.23) and high doses
(aRR of 2.11) versus low doses (aRR of 1.13), although only
the risk associated with the medium dose was statistically
significant.
3.6. Outcomes Stratified by Duration of Treatment. Table 6
summarizes results related to cardiac mortality and all-cause
mortality by duration of treatment (<1 year, 1–3 years, and
longer than 3 years) relative to nonusers with psychiatric
illness. Among patients currently taking olanzapine, the risk
of all-cause and cardiac mortality was lowest for those who
had been treated for >3 years. The risk of cardiac mortality
was significantly elevated for patients receiving olanzapine for
<1 or 1 to 3 years, but the risk of all-cause mortality was only
significantly elevated for patients receiving olanzapine for <1
year. Among the larger group of all antipsychotic users, the
overall cardiac mortality risk was significantly elevated for
all 3 duration strata; however, the risk decreased as duration
of use increased, which is similar to the trend seen with
users of olanzapine. For CHD and ventricular arrhythmia,
very small differences were seen between the duration of
treatment strata for olanzapine and for overall typical and
atypical antipsychotic drug users (data not shown). Again,
due to small counts, analyses did not produce reliable results
for comparison of strata by duration of treatment for any of
the three definitions of SCD for current users of olanzapine.
3.7. Comparison to Unexposed, Nonpsychiatric Population.
While previous results describe findings within the olanzap-
ine cohort relative to nonusers with psychiatric illness, a com-
parison with the general population (i.e., age- and gender-
matched patients without schizophrenia, major depression,
etc.) was also conducted. This cohort comprised 544,726
individuals. Despite differences in baseline psychiatric illness,
risks for all-cause cardiac mortality, SCD, CHD, and ven-
tricular arrhythmia outcomes for current users of olanzapine
relative to the general population were similar to risks for
these outcomes relative to nonusers with psychiatric illness.
However, there was a difference found in the all-cause
mortality comparison for olanzapine: risk for olanzapine
users was higher relative to the general population (aRR: 1.87,
95% CI, 1.69–2.08) than the risk relative to nonusers with
psychiatric illness (aRR: 1.04, 95% CI, 0.93–1.17).
4. Discussion
Patients treated with olanzapine had a significantly increased
risk of cardiac mortality relative to psychiatric patients
not using antipsychotics. The number of SCD events in
olanzapine users was too low to calculate risk ratios. Patients
treated with olanzapine were not shown to have higher risk
for CHD and ventricular arrhythmia relative to nonusers,
such that it is unclear what led to the increased risk of
cardiovascular mortality overall. Although we found that
the rates of CHD between the exposed cohort compared
to psychiatric nonusers were similar, this observation may
be partly explained by the very narrow definition used to
identify CHD in the study. Increased risk for adverse car-
diovascular outcomes among patients with schizophrenia has
previously been reported [11, 12], and the olanzapine-treated
population had a markedly higher proportion of patients
with schizophrenia than did the nonuser cohort; however,
this does not explain why risk for cardiac mortality was
increased, whereas risk for the secondary outcomes of CHD
and ventricular arrhythmias was not increased. Furthermore,
patients treated with olanzapine were not found to be at
significantly increased risk of all-cause mortality relative to
psychiatric nonusers.
Olanzapine patients, age 30–64, were found to be at
significantly higher risk for several of the outcomes (all-cause
and cardiac mortality) than patients in older age strata; there
were too few patients/events in the <30 age group for ade-
quate assessment of younger patients. Generally, the lowest
risk was for patients ≥ 80 years old. The lower magnitude
of risk in people in the oldest age stratum may represent
a healthy survivor effect. No patterns were observed that
suggested that increased risk was associated with increased
duration of olanzapine use, which contradicts the hypothesis
that increased risk of adverse cardiac outcomes associated
with olanzapine use may be via a metabolic mechanism of
action. However, it is possible that negative cardiac outcomes
might have been avoided if, for example, patientswith adverse
metabolic changes early in treatment discontinued drug
earlier than patients without such changes.
In this study, use of antipsychotic agents in general,
whether typical or atypical, was associatedwith increased risk
of all-cause mortality and of cardiac mortality. In addition,
users of antipsychotic agents had an increased risk of SCD.
We compared the results from our study to those in other
available studies of the cardiovascular risk with antipsychotic
use. Ray et al. [2] calculated the adjusted incidence of SCD
among current users of atypical antipsychotic drugs in a ret-
rospective cohort study of Medicaid enrollees in Tennessee.
This study reported an elevated risk of SCD (aRR 2.26; 95%
CI, 1.88–2.72) among atypical antipsychotic users compared
to a nonuser psychiatric population.The present study results
show a similar finding when using the secondary definition
of SCD (aRR 1.79; 95% CI, 1.33–2.42; note that the secondary
definition of SCD used in the current study is the one most
consistent with that used by Ray et al.). In the current study,
the risk for SCD relative to nonusers was over twice as high
for typical antipsychotics as for atypical antipsychotics (aRR
3.99, 95% CI, 1.29–12.40 versus 1.79, 95% CI, 1.33–2.42); this
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Table 4: All-cause mortality (excluding suicide), cardiac mortality, and sudden cardiac death: current antipsychotic use versus nonuser
psychiatric.
Outcome Treatment Number ofevents PY
Incidence rate per
1000 PY
(95%CI)
Fully adjusted RR
(aRR)
(95%CI)
All-cause mortality
Nonuser psychiatric 7765 307,276 25.3 (24.7–25.8) Reference
Amisulpride 503 5220 96.4 (88.1–105.2) 1.51 (1.37–1.66)‡
Chlorpromazine 1553 28,550 54.4 (51.7–57.2) 1.59 (1.49–1.69)‡
Haloperidol 5552 21,045 263.8 (256.9–270.9) 2.33 (2.12–2.56)‡
Olanzapine 1305 34,985 37.3 (35.3–39.4) 1.04 (0.93–1.17)
Perphenazine 260 8507 30.6 (27.0–34.5) 1.30 (0.91–1.85)
Quetiapine 1887 17,216 109.6 (104.7–114.7) 1.42 (1.34–1.50)‡
Risperidone 3600 33,917 106.1 (102.7–109.7) 1.64 (1.56–1.72)‡
Cardiac mortality
Nonuser psychiatric 1289 200,988 6.4 (6.1–6.8) Reference
Amisulpride 98 3936 24.9 (20.2–30.3) 2.50 (1.76–3.57 )‡
Chlorpromazine 161 15,220 10.6 (9.0–12.3) 1.70 (1.11–2.58) )†
Haloperidol 522 11,546 45.2 (41.4–49.3) 2.10 (1.59–2.77) ‡
Olanzapine 206 26,765 7.7 (6.7–8.8) 1.53 (1.12– 2.09) ‡
Perphenazine 22 3232 6.8 (4.3–10.3) 0 (NC)
Quetiapine 344 15,183 22.7 (20.3–25.2) 1.79 (1.38–2.33)‡
Risperidone 543 25,024 21.7 (19.9–23.6) 1.87 (1.44 –2.41)‡
Sudden cardiac
death (secondary
definition)
Nonuser psychiatric 98 23,873 4.1 (3.3–5.0) Reference
Amisulpride 15 674 22.3 (12.5–36.7) 0 (NC)
Chlorpromazine 10 1297 7.7 (3.7–14.2) 0 (NC)
Haloperidol 47 1236 38.0 (28.0–50.6) 4.33 (3.03–6.17)‡
Olanzapine 10 3454 2.9 (1.4–5.3) 0 (NC)
Perphenazine 0 221 0.0 (0.0–16.7) 0 (NC)
Quetiapine 46 3407 13.5 (9.9–18.0) 1.51 (1.04–2.19)†
Risperidone 17 2187 7.8 (4.5–12.4) 0 (NC)
∗
𝑃 < 0.10; †𝑃 < 0.05; ‡𝑃 < 0.01.
Abbreviations: aRR: adjusted relative risk; CI: confidence interval; NC: not calculated; PY: person-years.
finding contrasts with Ray’s finding of more similar rate
ratios for SCD among current users of typical and atypical
antipsychotics (aRR 1.99, 95% CI, 1.68–2.34 versus 2.26, 95%
CI, 1.88–2.72). Ray et al. also reported an increasing risk of
SCDwith the increasing atypical antipsychotic dose, a finding
which was not borne out in the present study, although
we did find increasing risk with increased doses of typical
antipsychotics. One noteworthy difference between Ray et al.
and the present study that could have affected outcomes is
that Ray’s cohort of antipsychotic users had a mean age of
46, while the cohort of antipsychotic users in our study had a
mean age of 60. This discrepancy is due to the nature of the
studied databases. Whereas patients of all ages are included
in the GPRD database, Ray et al. studied patients enrolled in
Medicaid, who leave Medicaid at the age of 65 to enroll in
Medicare.
One limitation of our study with respect to assessment of
risk for SCD is that accurately identifying cases of SCD from
electronic medical record codes are inherently challenging.
In an effort to overcome the known limitations [13], we also
used free text searches. Cases were counted as SCD based
on coding algorithms unless the available free text clearly
specified another cause of death. However, this approach was
still limited, as many cases had little or no free text, and often
the free text said nothing more than “sudden death” or “died
suddenly.”Whenmore informationwas available, it was often
determined that the patient did not experience SCD (e.g.,
deaths due to motor vehicle accident, drug overdose). These
factors suggest a relatively high number of false positives.
Given these concerns, along with the relatively small number
of cases overall, data regarding SCD must be interpreted
cautiously.
Enger et al. [5] compared the risk of all-cause mor-
tality (excluding suicide), cardiovascular mortality, acute
myocardial infarction (MI), and arrhythmias in people with
schizophrenia who use antipsychotic medications to risks
in individuals without schizophrenia in a large managed
care organization. Our analysis assessing risk of all-cause
mortality for users of any antipsychotic relative to psychiatric
nonusers (1.75 [95% CI, 1.64–1.87]) is consistent with that
in Enger et al. (2.18 [95% CI, 1.14–4.18]). Among atypical
antipsychotic users, the aRR for all-cause mortality in the
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Table 5: Relative risks of all-cause mortality (excluding suicide) and cardiovascular outcomes for current users of various types of
antipsychotics versus nonuser psychiatric controls stratified by dose.
Outcome Exposure type ofcurrent users Dose
Outcome
events
Person-time
(Years)
Incidence rate per
1000 PY
(95%CI)
Fully adjusted RR
(aRR)
(95%CI)
All-cause mortality
Nonuser psychiatric NA 7765 307,276 25.3 (24.7–25.8) Reference
Atypical or typical
Low 21,208 218,635 97.0 (95.7–98.3) 1.72 (1.62–1.84)‡
Medium 1978 37,704 52.5 (50.2–54.8) 1.94 (1.80–2.10)‡
High 655 20,553 31.9 (29.5–34.4) 1.89 (1.71–2.09)‡
Atypical
Low 5969 51,838 115.2 (112.3–118.1) 1.51 (1.40–1.64)‡
Medium 1106 28,874 38.3 (36.1–40.6) 1.54 (1.40–1.69)‡
High 281 13,401 21.0 (18.6–23.6) 1.48 (1.29–1.71)‡
Typical
Low 14,528 160,264 90.7 (89.2–92.1) 1.76 (1.63–1.89)‡
Medium 683 4232 161.4 (149.5–174.0) 3.74 (3.36–4.15)‡
High 262 2509 104.4 (92.2–117.9) 3.61 (3.14–4.16)‡
Olanzapine
Low 873 17,172 50.8 (47.5–54.3) 1.00 (0.88–1.13)
Medium 323 12,304 26.3 (23.5–29.3) 1.07 (0.92–1.24)
High 109 5509 19.8 (16.3–23.9) 1.20 (0.97–1.49)∗
Cardiac Mortality
Nonuser psychiatric NA 1289 200,988 6.4 (6.1–6.8) Reference
Atypical or typical
Low 2157 107,874 20.0 (19.2–20.9) 1.65 (1.36–2.00)‡
Medium 251 25,299 9.9 (8.7–11.2) 2.10 (1.68–2.63)‡
High 70 12,470 5.6 (4.4–7.1) 2.27 (1.68–3.07)‡
Atypical
Low 984 42,824 23.0 (21.6–24.5) 1.35 (1.24–1.47)‡
Medium 173 21,258 8.1 (7.0–9.5) 1.67 (1.42–1.97)‡
High 43 9202 4.7 (3.4–6.3) 1.84 (1.35–2.51)‡
Typical
Low 1108 61,999 17.9 (16.8–19.0) 1.82 (1.44–2.32)‡
Medium 57 1862 30.6 (23.2–39.7) 3.40 (2.39–4.83)‡
High 15 1053 14.3 (8.0–23.5) 3.13 (1.79–5.47)‡
Olanzapine
Low 129 13,897 9.3 (7.8–11.0) 1.31 (0.93–1.82)
Medium 60 8851 6.8 (5.2–8.7) 2.06 (1.41–3.01)‡
High 17 4016 4.2 (2.5–6.8) 2.37 (1.36–4.12)‡
SCD (secondary
definition)
Nonuser psychiatric NA 98 23,873 4.1 (3.3–5.0) Reference
Atypical or typical
Low 157 11,914 13.2 (11.2–15.4) 2.09 (1.60–2.75)‡
Medium 14 2956 4.7 (2.6–8.0) 2.42 (1.35–4.35)‡
High 7 1274 5.5 (2.2–11.3) 3.36 (1.50–7.50)‡
Atypical
Low 82 6469 12.7 (10.1-15.7) 1.78 (1.31–2.42)‡
Medium 6 2660 2.3 (0.8–4.9) 1.32 (0.57–3.05)
High 2 1072 1.9 (0.2–6.7) 1.53 (0.37–6.39)
Typical
Low 70 5202 13.5 (10.5–17.0) 2.48 (1.81–3.40)‡
Medium 5 156 32.1 (10.4–74.8) 6.07 (2.45–14.99)‡
High 3 57 52.8 (10.9–154.3) 10.05 (3.15–32.08)‡
Olanzapine
Low 8 1951 4.1 (1.8–8.1) 0 (NC)
Medium 2 1052 1.9 (0.2–6.9) 0 (NC)
High 0 451 0.0 (0.0-8.2) 0 (NC)
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Table 5: Continued.
Outcome Exposure type ofcurrent users Dose
Outcome
events
Person-time
(Years)
Incidence rate per
1000 PY
(95%CI)
Fully adjusted RR
(aRR)
(95%CI)
CHD
Nonuser psychiatric NA 982 278,330 3.5 (3.3–3.8) Reference
Atypical or typical
Low 1192 185,032 6.4 (6.1–6.8) 1.19 (0.96–1.48)
Medium 126 33,440 3.8 (3.1–4.5) 1.15 (0.88–1.50)
High 37 17,757 2.1 (1.5 –2.9) 0.86 (0.59–1.26)
Atypical
Low 328 48,223 6.8 (6.1–7.6) 0.94 (0.72–1.23)
Medium 95 26,059 3.7 (3.0–4.5) 1.11 (0.81–1.51)
High 21 11,833 1.8 (1.1–2.7) 0.77 (0.47–1.26)
Typical
Low 843 131,363 6.4 (6.0–6.9) 1.40 (1.10–1.78)‡
Medium 20 3413 5.9 (3.6–9.1) 1.25 (0.76–2.05)
High 10 2001 5.0 (2.4–9.2) 1.54 (0.80–2.98)
Olanzapine
Low 76 15,856 4.8 (3.8–6.0) 0.99 (0.68–1.45)
Medium 46 11,029 4.2 (3.1–5.6) 1.34 (0.89–2.01)
High 10 4921 2.0 (1.0–3.7) 0.82 (0.42–1.63)
Ventricular
arrhythmias
Nonuser psychiatric NA 500 279,243 1.8 (1.6–2.0) Reference
Atypical or typical
Low 540 186,417 2.9 (2.7–3.2) 1.13 (0.99–1.29)∗
Medium 70 33,445 2.1 (1.6–2.6) 1.27 (0.98–1.64)∗
High 36 17,784 2.0 (1.4–2.8) 1.55 (1.08–2.20)†
Atypical
Low 163 48,398 3.4 (2.9–3.9) 1.03 (0.85–1.24)
Medium 48 26,079 1.8 (1.4–2.4) 1.12 (0.83–1.51)
High 19 11,842 1.6 (1.0–2.5) 1.27 (0.79–2.02)
Typical
Low 359 132,550 2.7 (2.4–3.0) 1.13 (0.98–1.31)∗
Medium 16 3416 4.7 (2.7–7.6) 2.23 (1.35–3.69)‡
High 7 2017 3.5 (1.4–7.2) 2.11 (0.99–4.47)∗
Olanzapine
Low 33 15,926 2.1 (1.4–2.9) 0.84 (0.59–1.20)
Medium 14 11,068 1.3 (0.7–2.1) 0.78 (0.46–1.33)
High 8 4927 1.6 (0.7–3.2) 1.22 (0.60–2.46)
∗
𝑃 < 0.10, †𝑃 < 0.05, ‡ 𝑃 < 0.01.
Abbreviations: aRR: adjusted relative risk; CHD: coronary heart disease; CI: confidence interval; NC: not calculable; PY: person-years; SCD: sudden cardiac
death.
current study was 1.52 (95% CI, 1.40–1.64) versus Enger’s
aRR of 1.47 (95% CI, 0.14–15.05); these values are similar,
but the wide confidence intervals in the Enger study should
be noted. Adjusted RRs for ventricular arrhythmias among
users of atypical antipsychotics are similar in both this
study (1.16 (95% CI, 1.02–1.31)) and that of Enger et al. (1.01
(95% CI, 0.09–11.28)), although the current study found a
statistically significant increased risk. Adjusted RRs for CHD
among users of atypical antipsychotics were nonsignificant
in both the current study (0.98 (95% CI, 0.76–1.26)) and
in that of Enger et al. (1.66 (95% CI, 0.19–14.82)). Of note,
the Enger study was composed of patients diagnosed only
with schizophrenia, whereas the present study population
included a broader psychiatric population with severemental
illness.
Osborn et al. [14] carried out a historical cohort study
comparingmortality fromCHD, cancer, and stroke between a
cohort of patients with severe mental illness (SMI), including
schizophrenia and bipolar disorder, and a cohort without
SMI, using GPRD. The risk of death was stratified by age,
use, and nonuse of antipsychotic agents (typical and atypical
combined), as well as by dose of antipsychotic agents. The
study found a higher relative rate of CHD-related death
among the 18–49 year age strata as compared to those
75+ (hazard rate 2.88 versus 1.04). Although there were
insufficient counts in the age stratum younger than 30 in the
current study, a similar trend of increased risk for younger
versus older patients was seen for both the CHD-related
deaths and all-cause mortality in the current study. Neither
Osborne et al. nor the current study showed a trend for
increasing CHD-related death as dose increased.
An 11-year population-based cohort study with follow-up
of mortality in schizophrenia patients [15] that is not directly
comparable to our study showed that long-term cumula-
tive exposure (7–11 years) to any antipsychotic treatment
was associated with lower all-cause mortality than was no
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Table 6: Relative risks of all-cause mortality (excluding suicide) and cardiac mortality for current users of various types of antipsychotics
versus nonuser psychiatric controls stratified by duration of treatment.
Outcome Exposure type of
current users
Duration of
treatment
Outcome
events
Person-time
(Years)
Incidence rate per
1000 PY
(95%CI)
Fully adjusted RR
(aRR)
(95%CI)
All-cause mortality
Nonuser psychiatric NA 7765 307,276 25.3 (24.7–25.8) Reference
Atypical or typical
<1 year 16,571 176,402 93.9 (92.5–95.4) 1.95 (1.83–2.08)‡
1–3 years 4861 56,041 86.7 (84.3–89.2) 1.53 (1.43–1.64)‡
>3 years 2409 44,449 54.2 (52.1–56.4) 1.20 (1.11–1.29)‡
Atypical
<1 year 4333 49,387 87.7 (85.1–90.4) 1.68 (1.55–1.82)‡
1–3 years 2068 26407 78.3 (75.0–81.8) 1.42 (1.31–1.55)‡
>3 years 955 18,318 52.1 (48.9–55.6) 1.15 (1.04–1.27)‡
Typical
<1 year 11,989 124,518 96.3 (94.6–98.0) 1.98 (1.84–2.13)‡
1–3 years 2430 24,906 97.6 (93.7–101.5) 1.56 (1.43–1.69)‡
>3 years 1054 17,581 60.0 (56.4–63.7) 1.17 (1.06–1.28)‡
Olanzapine
<1 year 659 18,111 36.4 (33.7–39.3) 1.21 (1.06–1.38)‡
1–3 years 395 9674 40.8 (36.9–45.1) 1.04 (0.91–1.20)
>3 years 251 7200 34.9 (30.7–39.5) 0.78 (0.67–0.91)‡
Cardiac mortality
Nonuser psychiatric NA 1289 200,988 6.4 (6.1–6.8) Reference
Atypical or typical
<1 year 1707 95,129 17.9 (17.1–18.8) 1.85 (1.53–2.24)‡
1–3 years 563 32,383 17.4 (16.0–18.9) 1.60 (1.30–1.95)‡
>3 years 208 18,131 11.5 (10.0–13.1) 1.31 (1.04–1.65)†
Atypical
<1 year 761 42,705 17.8 (16.6–19.1) 1.51 (1.38–1.66)‡
1–3 years 315 20,399 15.4 (13.8–17.2) 1.26 (1.11–1.43)‡
>3 years 124 10,180 12.2 (10.1–14.5) 1.16 (0.97–1.41)
Typical
<1 year 918 50,850 18.1 (16.9–19.3) 1.92 (1.51–2.45)‡
1–3 years 204 9216 22.1 (19.2–25.4) 1.75 (1.34–2.28)‡
>3 years 58 4848 12.0 (9.1–15.5) 1.21 (0.86–1.71)
Olanzapine
<1 year 111 15,615 7.1 (5.9–8.6) 1.67 (1.18–2.35)‡
1–3 years 65 7269 8.9 (6.9–11.4) 1.57 (1.09–2.26)†
>3 years 30 3881 7.7 (5.2–11.0) 1.24 (0.79–1.94)
∗
𝑃 < 0.10, †𝑃 < 0.05, ‡𝑃 < 0.01.
Abbreviations: aRR: adjusted relative risk; CI: confidence interval; NC: not calculable; PY: person-years.
antipsychotic use (aRR 0.8 [95% CI: 0.77–0.84]). There were
no significant differences in risk of death from ischaemic
heart disease among all the antipsychotics studied (risperi-
done, thioridazine, quetiapine, haloperidol, perphenazine,
clozapine, and olanzapine). Olanzapine was not associated
with an increase in risk of mortality from ischaemic heart
disease when compared with perphenazine (aRR 0.88 [95%
CI: 0.63–1.21]) andwas associated with a lower total mortality
and deaths due to ischaemic heart diseases than the other
antipsychotics [15].
More recently, Leonard et al. [16] calculated adjusted haz-
ard ratios (HR) of SCD or VA (together) and all-cause death
among users of antipsychotic drugs in a retrospective cohort
of Medicaid enrollees in California, Florida, New York, Ohio,
and Pennsylvania. Compared to olanzapine as the referent,
adjusted HRs for SCD/VA were 2.06 (95% CI, 1.20–3.53) for
chlorpromazine, 1.72 (1.28–2.31) for haloperidol, 0.63 (0.34–
1.16) for perphenazine, 0.73 (0.57–0.93) for quetiapine, and
1.04 (0.88–1.24) for risperidone. These results are consistent
with our study findings suggesting greater cardiac risks for
users of typical antipsychotics versus atypical antipsychotics.
Our study did not evaluate mechanisms that might
explain increased risk in cardiac mortality among antipsy-
chotic users; however, 2 main mechanisms have been pro-
posed. The first mechanism is blockade of potassium chan-
nels and prolongation of ventricular repolarization, which
can contribute to potentially fatal ventricular arrhythmias.
As such, prolongation of the QTc interval is considered a
reasonable marker of increased risk [1, 17]. An increased
risk of mortality was observed in patients treated with
some antipsychotics which are associated with prolongation
of the QT interval and/or adverse changes in metabolic
parameters. Antipsychotics vary with respect to the risk of
prolonged QT interval, however, and sometimes mortality
findings for patients taking medications known to increase
QT do not suggest increased risk of acute death; for example,
thioridazine, a known inducer of prolonged QT, was not
associated with high all-cause mortality in an analysis of
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current use [15]. Leonard et al. [16] also found that risks
for SCD/VA and death did not correlate well with average
QT prolongation, suggesting that average QT prolongation
may be a poor surrogate of antipsychotic arrhythmogenicity.
Previous analyses of clinical trial data have suggested that
olanzapine does not increase the risk of QTc prolongations
that lead to potentially fatal ventricular arrhythmias [18,
19]; this is supported by findings of the present study that
patients treated with olanzapine were not at increased risk
of ventricular arrhythmias despite being at increased risk of
cardiac mortality in general.
An alternative, or perhaps additional, explanation for
increased risk of sudden cardiac death or cardiovascular
disease during treatment with antipsychotics could be the
increased risk of metabolic changes associated with psychi-
atric disorders. Patients with schizophrenia or other psy-
chiatric disorders have a higher prevalence of diabetes [14]
and/or cardiovascular disease-related morbidity and mortal-
ity as compared to the general population [11, 20]. Depression
is also a known risk factor formortality due to coronary heart
disease [21]. More than 80% of cases of sudden cardiac death
occur in individuals with coronary heart disease [15]. SCD
occurs in only 5% to 10% of subjects without a positive history
for coronary heart disease or congestive heart failure, and the
most common electrophysiological mechanisms leading to
SCD are ventricular tachyarrhythmias [22].
As anticipated, there was a significant discrepancy in
the distribution of psychiatric illnesses across the user and
nonuser groups. The most commonly identified psychiatric
diagnosis for the olanzapine cohort was schizophrenia (18%)
followed by major depression (16%) and bipolar disorder
(10%). Fifty percent of this group had no reported psychiatric
diagnosis, although it is likely that many of the olanzapine
users without a reported psychiatric diagnosis in fact had
schizophrenia.This distribution sharply contrasts with that of
the nonuser psychiatric population, where the majority had a
diagnosis of major depression (69%) followed by dementia
(24%), with only 4% having a diagnosis of schizophrenia
and 2%, bipolar disorder. The discrepancy in presence of
diagnosis in the database may be partly explained by the
fact that more specific mental health diagnoses are likely
to be made in secondary care or in the community mental
health setting and may not be communicated in a detailed
manner back to the general practice; furthermore, there may
be stigma associatedwith psychiatric disorders thatmay deter
documentation. To assess the impact of underlying psychi-
atric disease, analyses stratified by underlying psychiatric
illness were performed.The results showed a 2-fold increased
risk of all-causemortality among patients with schizophrenia
(aRR 1.99, 95% CI, 1.50–2.65) as compared to the general
population.Major depression had a slight increased risk (aRR
1.05, 95% CI 0.98–1.12) compared to the general population.
The other psychiatric disorders analyzed had similar risks
with an aRR of 1.45 (95% CI, 1.40–1.50) for dementia and 1.40
(95%CI, 1.01–1.95) for bipolar disorders. It is possible that the
imbalance of psychiatric illness between the study cohorts
could have contributed to the higher mortality rates among
patients taking antipsychotic agents.
This study was based on a large nationally representative
community sample of patients diagnosed with psychiatric
disease with exposure to antipsychotic agents.The large sam-
ple size allowed for systematic evaluation of cardiovascular
outcomes of interest (with the exception of SCD due to a
limited number of events and validity issues). The sudden
cardiac death definition was restricted by the lack of precise
timing of the sequence of events that lead to an out of
hospital death and the limited clinical detail in the GPRD
records. This study attempted to control for differences in
patients characteristics; however, it is important to note that
some characteristicsmay not have been adequately controlled
for (such as smoking status and physical activity). Another
limitation of the study is the inherent difficulty in sorting
out the myriad influences on patient outcomes, including the
natural course of illness, the positive effects of treating the
illness on general health practices, and the potential adverse
events during treatment with medication.
We did not assess the validity of the outcomes of interest
to this study as the data that are needed to support robust
validation, for example, detailed echocardiography report
and coroner’s reports, are not widely available in secondary
sources of data such as GPRD and Hospital Episode Statistic
data. Failure to validate outcomes across the different sources
of data is another limitation of this analysis of the potential
association between cardiac mortality and treatment with
olanzapine.
Finally, our observed association between antipsychotic
prescribing and cardiac mortality may have been better
addressed using propensity score-matched analyses. Not only
would such analyses provide insights into the treatment
allocation process with respect to known variables and
provide estimates that were standardized to the treated
population, but also they could potentially minimize issues
of confounding by indication that is common among the
psychiatric populations. However, we elected to undertake
a matched analysis that was not based on propensity scores
matching due to concerns relating to reduction of our sample
size and the associated effect on statistical power to detect an
association especially given that sudden cardiac deathwas not
a common reported outcome.
5. Conclusions
The use of antipsychotic agents in general, whether typical
or atypical, was associated with increased risk of all-cause
and cardiac mortality. Relative to patients with psychiatric
illness who were not exposed to antipsychotic medications
olanzapine users demonstrated a significantly increased risk
of cardiac mortality, but no increased risk of all-cause
mortality. Given concerns regarding the validity of the SCD
diagnosis, along with the relatively small number of cases
overall, data regarding SCD must be interpreted cautiously.
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